The preview of a sealed court document shows a Delaware judge ruled in favor of Valeant on two issues of four. Valeant and Actavis — whose parent is Teva Pharmaceuticals ( TEVA ) — will resolve one issue outside of court. The judge also extended a 30-month stay preventing Actavis from creating a generic copy of Xifaxan. IBD'S TAKE: There's been some chatter that Valeant's spike could be related to short interest. What would that look like on a chart? Head to The Short Side for a closer look. Actavis' 30-month stay was originally slated to expire in August 2018 with a district court trial scheduled for the end of January 2018. Though Valeant stock spiked this week, the increase likely wasn't related to the drugmaker's first-quarter earnings report. On Tuesday, Valeant reported $2.11 billion in sales, missing the consensus for $2.18 billion.